Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases.
We examine the effect of nasal sumatriptan as an adjunctive therapy in 3 patients with idiopathic trigeminal neuralgia refractory to carbamazepine (CBZ) and found that this therapy might be suitable for patients for whom the CBZ dose cannot be increased, who are under poor pain control, and who are not candidates for nerve blocks or surgery.
Shimohata
Keiko
K
Takasaki Pain Clinic, Takasaki, Gunma, Japan.
Shimohata
Takayoshi
T
Motegi
Ryoichiro
R
Miyashita
Kou
K
D000281:Administration, Intranasal; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage; D002220:Carbamazepine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000502:physiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D020078:Neurogenic Inflammation / Q000188:drug therapy / Q000503:physiopathology; D009479:Neuropeptides / Q000037:antagonists & inhibitors / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D018170:Sumatriptan / Q000008:administration & dosage*; D016896:Treatment Outcome; D014276:Trigeminal Nerve / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D014277:Trigeminal Neuralgia / Q000188:drug therapy* / Q000503:physiopathology
D000927:Anticonvulsants; D009479:Neuropeptides; D017366:Serotonin Receptor Agonists; D002220:Carbamazepine; D018170:Sumatriptan